GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (CHIX:SANp) » Definitions » Current Deferred Revenue

Sanofi (CHIX:SANP) Current Deferred Revenue : €0 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sanofi Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sanofi's current deferred revenue for the quarter that ended in Jun. 2024 was €0 Mil.

Sanofi Current Deferred Revenue Historical Data

The historical data trend for Sanofi's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Current Deferred Revenue Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 321.00 319.00 269.00 -

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 269.00 - - -

Sanofi Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Sanofi's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (CHIX:SANp) » Definitions » Current Deferred Revenue
Comparable Companies
XPAR:VIRP LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG XSWX:NOVN LSE:AZN AMGN PFE BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 BIIB XTER:BAYN
Traded in Other Exchanges
SNYNF:USA SNY:USA SNY:Mexico 1SAN:Italy 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria
Address
46, avenue de la Great Army, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.